The thiazolidinediones, rosiglitazone and pioglitazone, have been associated with an increased risk of congestive heart failure most likely due to a greater incidence of fluid retention/edema associated with this drug class. Patients should be closely monitored for signs and symptoms of CHF, and thiazolidinedione dosages reduced or discontinued should symptoms develop. Thiazolidinediones are contraindicated for use in NYHA Class III or IV heart failure and are not recommended in patients with symptomatic heart failure.
Recent data have documented an increased risk of heart attack and heart-related deaths in patients prescribed rosiglitazone. The FDA have determined that while the evidence documenting increased cardiovascular ischemic risks with rosiglitazone are not robust or consistent, there are enough areas of concern to warrant significant restrictions on rosiglitazone use. Rosiglitazone is now only approved for use in patients with type 2 diabetes who cannot maintain glycemic control with any other antidiabetic medication.
Female patients treated with thiazolidinediones may be at increased risk for developing fractures. These agents have been shown to stimulate formation of more adipocytes rather than osteoblasts in bone. Thiazolidinediones may also decrease hip and femoral neck bone mineral density in older diabetic patients. Fractures currently reported with thiazolidinedione use have been limited to the humerus, hand and foot in female patients only. Further assessment of thiazolidinedione adverse skeletal effects is necessary to determine the risk-benefit ratio of these agents in diabetic patients. Female patients at higher fracture risk should be considered for bone mineral density assessment and bone strengthening therapies (e.g., calcium, vitamin D, bisphosphonates) prior to therapy initiation with thiazolidinediones.
Adults
Maximum recommended daily doses for available oral antidiabetic agents, both as monotherapy and as combination therapy, are summarized in Tables 1 and 2 . Prescribed dosages exceeding these recommendations will be reviewed. Sitagliptin dosages should be adjusted in adult patients with renal insufficiency. Patients with moderate renal insufficiency (CrCl > 30 to < 50 ml/min corresponding to serum creatinine levels between 1.7 and 3 mg/dl in men and 1.5 and 2.5 mg/dl in women) should receive sitagliptin 50 mg daily, while patients with severe renal insufficiency (CrCl < 30 ml/min corresponding to serum creatinine levels in men > 3 mg/dl or > 2.5 mg/dl in women) or those patients with end stage renal disease requiring hemodialysis or peritoneal dialysis should receive sitagliptin 25 mg daily. Saxagliptin dosages should be reduced to 2.5 mg once daily in patients with CrCl < 50 ml/min or in patients prescribed a strong CYP3A4 inhibitor (e.g., ketoconazole). Linagliptin dosages do not need to be adjusted for renal insufficiency. Patients on linagliptin combination therapy with a CrCl < 30 ml/min may have increased risk of hypoglycemia and may need more frequent monitoring and/or dose adjustments.
Simvastatin/sitagliptin is the only approved combination drug that has a lipid lowering drug and DPP-IV inhibitor.
Pediatrics
Oral sulfonylureas, alpha-glucosidase inhibitors, pioglitazone, meglitinides and DPP-4 inhibitors are not FDA-approved for use in pediatric patients as safety and efficacy have not been determined in this patient population. Sufficient data are not available to assess rosiglitazone safety and efficacy in pediatric patients. Metformin immediate-release is FDA-approved for use in pediatric type 2 diabetic patients 10 years of age and older as an adjunct to diet in exercise to aid in controlling blood glucose. Maximum recommended oral antidiabetic doses in pediatric patients are summarized in Table 3 . Dosages exceeding these recommendations will be reviewed. 
. Duration of Therapy
There is no basis for limiting the duration of oral antidiabetic therapy as diabetes is a chronic disorder.
3.* Duplicative Therapy
Administering two or more oral sulfonylureas concurrently is not justified. The concomitant use of two or more oral sulfonylureas will be reviewed.
The combined use of nateglinide or repaglinide and oral sulfonylureas is not justified as both drug classes stimulate insulin secretion. Concurrent administration of nateglinide or repaglinide and oral sulfonylureas will be reviewed.
The risk of hypoglycemia may increase when acarbose or miglitol is added to pre-existing oral hypoglycemic or insulin therapy. Blood glucose levels should be monitored closely when alpha glucosidase inhibitor therapy is initiated in patients already receiving oral hypoglycemic or insulin therapy.
Adjunctive administration of rosiglitazone and insulin is not recommended as a greater incidence of myocardial ischemic events was observed in clinical trials when rosiglitazone was added to insulin therapy.
Concurrent administration of thiazolidinediones or metformin with sulfonylureas may result in an increased frequency of hypoglycemic episodes. Blood glucose levels should be closely monitored if patients are prescribed thiazolidinediones or metformin and oral sulfonylureas concomitantly, and oral sulfonylurea dosage reductions should be considered.
Concurrent administration DDP-4 inhibitors and sulfonylureas, with or without metformin, have resulted in significant reductions in HbA1c and fasting plasma glucose compared to placebo. The risk of hypoglycemia with DDP-4 inhibitors in combination with metformin and TZDs is comparable to that observed with placebo; however the incidence of hypoglycemia in patients prescribed DDP-4 inhibitors concurrently with sulfonylureas is greater than that seen with placebo. The incidence of hypoglycemia in patients prescribed DDP-4 inhibitors and insulin concurrently has not been adequately evaluated. Therefore, blood glucose levels should be closely monitored if patients are prescribed DDP-4 inhibitors and oral sulfonylureas or insulin concomitantly, and oral sulfonylurea dosage reductions should be considered.
4.* Drug-Drug Interactions
Patient profiles will be reviewed to identify those drug regimens which may result in clinically significant drug-drug interactions. Drug-drug interactions considered clinically relevant for oral antidiabetic agents are summarized in Table 4 . Only those drug-drug interactions classified as clinical significance level 1 or those considered lifethreatening which have not yet been classified will be reviewed: 
